Inhibition of autophagy flux by sertraline attenuates TRAIL resistance in lung cancer via death receptor 5 upregulation

Zinnah,Kazi Mohammad Ali; Seol,Jae‑Won; Park,Sang‑Youel

doi:10.3892/ijmm.2020.4635

Inhibition of autophagy flux by sertraline attenuates TRAIL resistance in lung cancer via death receptor 5 upregulation

Authors:
- Kazi Mohammad Ali Zinnah
- Jae‑Won Seol
- Sang‑Youel Park
View Affiliations

Affiliations: Biosafety Research Institute, College of Veterinary Medicine, Jeonbuk National University, Iksan, Jeonbuk 54596, Republic of Korea
Published online on: June 5, 2020 https://doi.org/10.3892/ijmm.2020.4635
Pages: 795-805
Copyright: © Zinnah et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL) is a potential target for cancer therapy, owing to its ability to selectively kill cancer cells without causing significant toxicity to normal cells. However, due to the lack of death receptor expression, cancer cells can become highly resistant to TRAIL. Hence, it is vital to develop agents that restore TRAIL efficacy. Sertraline is an antidepressant drug with anticancer properties. To the best of our knowledge, this is the first study to demonstrate that sertraline inhibits autophagic flux and increases the expression of death receptor 5 (DR5) on TRAIL‑resistant lung cancer cells. Inhibition of autophagy using autophagy inhibitors 3‑methyladenine and chloroquine upregulated the expression of DR5 and enhanced TRAIL‑induced apoptosis, as confirmed by the increase of pro‑apoptotic proteins caspase‑8 and caspase‑3. Silencing DR5 expression using DR5 small interfering RNA prevented sertraline‑induced TRAIL‑mediated apoptosis, indicating the role of DR5 in TRAIL‑mediated apoptosis. Overall, sertraline enhanced TRAIL‑mediated apoptosis via the downregulation of AMP‑activated protein kinase phosphorylation, resulting in the inhibition of autophagic flux, upregulation of DR5 expression, and activation of the apoptotic caspase cascade. These data suggested that sertraline could be used to sensitize human lung cancer cells to TRAIL, while also serving as a therapeutic option in cancer patients with depression.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Zingone A, Brown D, Bowman ED, Vidal O, Sage J, Neal J and Ryan BM: Relationship between anti-depressant use and lung cancer survival. Cancer Treat Res Commun. 10:33–39. 2017. View Article : Google Scholar : PubMed/NCBI
3	Schelhaas S, Held A, Wachsmuth L, Hermann S, Honess DJ, Heinzmann K, Smith DM, Griffiths JR, Faber C and Jacobs AH: Gemcitabine mechanism of action confounds early assessment of treatment response by 3′-Deoxy-3′-[18F]Fluorothymidine in preclinical models of lung cancer. Cancer Res. 76:7096–7105. 2016. View Article : Google Scholar : PubMed/NCBI
4	Garcia G and Odaimi M: Systemic combination chemotherapy in elderly pancreatic cancer: A review. J Gastrointest Cancer. 48:121–128. 2017. View Article : Google Scholar : PubMed/NCBI
5	Sun W, Sanderson PE and Zheng W: Drug combination therapy increases successful drug repositioning. Drug Discov Today. 21:1189–1195. 2016. View Article : Google Scholar : PubMed/NCBI
6	Uchibori K, Inase N, Araki M, Kamada M, Sato S, Okuno Y, Fujita N and Katayama R: Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun. 8:147682017. View Article : Google Scholar : PubMed/NCBI
7	Aggarwal BB: Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol. 3:745–756. 2003. View Article : Google Scholar : PubMed/NCBI
8	Mellier G, Huang S, Shenoy K and Pervaiz S: TRAILing death in cancer. Mol Aspects Med. 31:93–112. 2010. View Article : Google Scholar
9	Nazim UM, Rasheduzzaman M, Lee YJ, Seol DW and Park SY: Enhancement of TRAIL-induced apoptosis by 5-fluorouracil requires activating Bax and p53 pathways in TRAIL-resistant lung cancers. Oncotarget. 8:18095–18105. 2017. View Article : Google Scholar : PubMed/NCBI
10	O'Leary L, van der Sloot AM, Reis CR, Deegan S, Ryan AE, Dhami SPS, Murillo LS, Cool RH, Sampaio PC, Thompson K, et al: Decoy receptors block TRAIL sensitivity at a supracellular level: The role of stromal cells in controlling tumour TRAIL sensitivity. Oncogene. 35:1261–1270. 2016. View Article : Google Scholar
11	Wang S and El-Deiry WS: TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 22:8628–8633. 2003. View Article : Google Scholar : PubMed/NCBI
12	Wang S: The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene. 27:6207–6215. 2008. View Article : Google Scholar : PubMed/NCBI
13	Wu GS: TRAIL as a target in anti-cancer therapy. Cancer Lett. 285:1–5. 2009. View Article : Google Scholar : PubMed/NCBI
14	Jin CY, Park C, Hwang HJ, Kim GY, Choi BT, Kim WJ and Choi YH: Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells. Mol Nutr Food Res. 55:300–309. 2011. View Article : Google Scholar
15	Dai X, Zhang J, Arfuso F, Chinnathambi A, Zayed ME, Alharbi SA, Kumar AP, Ahn KS and Sethi G: Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. Exp Biol Med (Maywood). 240:760–773. 2015. View Article : Google Scholar
16	Ding J, Polier G, Köhler R, Giaisi M, Krammer PH and Li-Weber M: Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression. J Biol Chem. 287:641–649. 2012. View Article : Google Scholar :
17	Mizushima N, Yoshimori T and Levine B: Methods in mammalian autophagy research. Cell. 140:313–326. 2010. View Article : Google Scholar : PubMed/NCBI
18	Tanida I, Minematsu-Ikeguchi N, Ueno T and Kominami E: Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy. 1:84–91. 2005. View Article : Google Scholar
19	Gómez-Sánchez R, Yakhine-Diop SMS, Rodríguez-Arribas M, Pedro JMB, Martínez-Chacón G, Uribe-Carretero E, de Castro DCJ, Pizarro-Estrella E, Fuentes JM and González-Polo RA: mRNA and protein dataset of autophagy markers (LC3 and p62) in several cell lines. Data Brief. 7:641–647. 2016. View Article : Google Scholar : PubMed/NCBI
20	Boya P, González-Polo R, Casares N, Perfettini J, Dessen P, Larochette N, Métivier D, Meley D, Souquere S, Yoshimori T, et al: Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol. 25:1025–1040. 2005. View Article : Google Scholar : PubMed/NCBI
21	Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema K, Coppes RP, Engedal N, Mari M and Reggiori F: Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 14:1435–1455. 2018. View Article : Google Scholar : PubMed/NCBI
22	Heckmann BL, Yang X, Zhang X and Liu J: The autophagic inhibitor 3-methyladenine potently stimulates PKA-dependent lipolysis in adipocytes. Br J Pharmacol. 168:163–171. 2013. View Article : Google Scholar :
23	Kahn BB, Alquier T, Carling D and Hardie DG: AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 1:15–25. 2005. View Article : Google Scholar : PubMed/NCBI
24	Zhou C, Gu J, Zhang G, Dong D, Yang Q, Chen M and Xu D: AMPK-autophagy inhibition sensitizes icaritin-induced anti-colorectal cancer cell activity. Oncotarget. 8:14736–14747. 2017. View Article : Google Scholar : PubMed/NCBI
25	Cho SW, Na W, Choi M, Kang SJ, Lee S and Choi CY: Autophagy inhibits cell death induced by the anti-cancer drug morusin. Am J Cancer Res. 7:518–530. 2017.PubMed/NCBI
26	Laoutidis ZG and Mathiak K: Antidepressants in the treatment of depression/depressive symptoms in cancer patients: A systematic review and meta-analysis. BMC Psychiatry. 13:1402013. View Article : Google Scholar : PubMed/NCBI
27	Serafin MB, Bottega A, da Rosa TF, Machado CS, Foletto VS, Coelho SS, da Mota AD and Hörner R: Drug repositioning in oncology. Am J Ther. 2019. View Article : Google Scholar
28	Xia D, Zhang Y, Xu G, Yan W, Pan X and Tong J: Sertraline exerts its antitumor functions through both apoptosis and autophagy pathways in acute myeloid leukemia cells. Leuk Lymphoma. 58:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
29	Alers S, Löffler AS, Wesselborg S and Stork B: Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: Cross talk, shortcuts, and feedbacks. Mol Cell Biol. 32:2–11. 2012. View Article : Google Scholar :
30	Di Rosso ME, Sterle HA, Cremaschi GA and Genaro AM: Beneficial effect of fluoxetine and sertraline on chronic stress-induced tumor growth and cell dissemination in a mouse model of lymphoma: Crucial role of antitumor immunity. Front Immunol. 9:13412018. View Article : Google Scholar : PubMed/NCBI
31	Dhabhar FS, Saul AN, Holmes TH, Daugherty C, Neri E, Tillie JM, Kusewitt D and Oberyszyn TM: High-anxious individuals show increased chronic stress burden, decreased protective immunity, and increased cancer progression in a mouse model of squamous cell carcinoma. PLoS One. 7:e330692012. View Article : Google Scholar : PubMed/NCBI
32	Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, et al: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 12:939–944. 2006. View Article : Google Scholar : PubMed/NCBI
33	Kim-Fuchs C, Le CP, Pimentel MA, Shackleford D, Ferrari D, Angst E, Hollande F and Sloan EK: Chronic stress accelerates pancreatic cancer growth and invasion: A critical role for beta-adrenergic signaling in the pancreatic microenvironment. Brain Behav Immun. 40:40–47. 2014. View Article : Google Scholar : PubMed/NCBI
34	Hassan S, Karpova Y, Baiz D, Yancey D, Pullikuth A, Flores A, Register T, Cline JM, D'Agostino Jr, Danial N, et al: Behavioral stress accelerates prostate cancer development in mice. J Clin Invest. 123:874–886. 2013.PubMed/NCBI
35	Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JMG, Morizono K, Karanikolas BDW, Wu L, et al: The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 70:7042–7052. 2010. View Article : Google Scholar : PubMed/NCBI
36	Hasegawa H and Saiki I: Psychosocial stress augments tumor development through beta-adrenergic activation in mice. Jpn J Cancer Res. 93:729–735. 2002. View Article : Google Scholar : PubMed/NCBI
37	Toh S, Rodríguez LAG and Hernández-Díaz S: Use of antidepressants and risk of lung cancer. Cancer Causes Control. 18:1055–1064. 2007. View Article : Google Scholar : PubMed/NCBI
38	Chou CT, He S and Jan CR: Paroxetine-induced apoptosis in human osteosarcoma cells: Activation of p38 MAP kinase and caspase-3 pathways without involvement of [Ca2+]i elevation. Toxicol Appl Pharmacol. 218:265–273. 2007. View Article : Google Scholar
39	Abdul M, Logothetis CJ and Hoosein NM: Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol. 154:247–250. 1995. View Article : Google Scholar : PubMed/NCBI
40	Spanová A, Kovárů H, Lisá V, Lukásová E and Rittich B: Estimation of apoptosis in C6 glioma cells treated with antidepressants. Physiol Res. 46:161–164. 1997.PubMed/NCBI
41	Amit BH, Gil-Ad I, Taler M, Bar M, Zolokov A and Weizman A: Proapoptotic and chemosensitizing effects of selective serotonin reuptake inhibitors on T cell lymphoma/leukemia (Jurkat) in vitro. Eur Neuropsychopharmacol. 19:726–734. 2009. View Article : Google Scholar : PubMed/NCBI
42	LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D and Ashkenazi A: Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med. 8:274–281. 2002. View Article : Google Scholar : PubMed/NCBI
43	Srivastava RK: TRAIL/Apo-2L: Mechanisms and clinical applications in cancer. Neoplasia. 3:535–546. 2001. View Article : Google Scholar
44	Bellail AC, Qi L, Mulligan P, Chhabra V and Hao C: TRAIL agonists on clinical trials for cancer therapy: The promises and the challenges. Rev Recent Clin Trials. 4:34–41. 2009. View Article : Google Scholar : PubMed/NCBI
45	Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 5:157–163. 1999. View Article : Google Scholar : PubMed/NCBI
46	Klionsky DJ: Autophagy: From phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol. 8:931–937. 2007. View Article : Google Scholar : PubMed/NCBI
47	Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB and Tsujimoto Y: Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol. 6:1221–1228. 2004. View Article : Google Scholar : PubMed/NCBI
48	Glick D, Barth S and Macleod KF: Autophagy: Cellular and molecular mechanisms. J Pathol. 221:3–12. 2010. View Article : Google Scholar : PubMed/NCBI
49	Park EJ, Min K, Choi KS, Kubatka P, Kruzliak P, Kim DE and Kwon TK: Chloroquine enhances TRAIL-mediated apoptosis through up-regulation of DR5 by stabilization of mRNA and protein in cancer cells. Sci Rep. 6:229212016. View Article : Google Scholar : PubMed/NCBI
50	Liu X, Chhipa RR, Nakano I and Dasgupta B: The AMPK inhibitor compound C is a potent AMPK-independent antiglioma agent. Mol Cancer Ther. 13:596–605. 2014. View Article : Google Scholar : PubMed/NCBI
51	Zinnah KMA and Park SY: Duloxetine enhances TRAIL-mediated apoptosis via AMPK-mediated Inhibition of autophagy flux in lung cancer cells. Anticancer Res. 39:6621–6633. 2019. View Article : Google Scholar : PubMed/NCBI
52	Yang Y, Hu L, Zheng H, Mao C, Hu W, Xiong K, Wang F and Liu C: Application and interpretation of current autophagy inhibitors and activators. Acta Pharmacol Sin. 34:625–635. 2013. View Article : Google Scholar : PubMed/NCBI
53	Hu X, Shi S, Wang H, Yu X, Wang Q, Jiang S, Ju D, Ye L and Feng M: Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo. Sci Rep. 7:45592017. View Article : Google Scholar : PubMed/NCBI
54	Lin YC, Lin JF, Wen SI, Yang SC, Tsai TF, Chen HE, Chou KY and Hwang TI: Chloroquine and hydroxychloroquine inhibit bladder cancer cell growth by targeting basal autophagy and enhancing apoptosis. Kaohsiung J Med Sci. 33:215–223. 2017. View Article : Google Scholar : PubMed/NCBI